Skip to main
LYEL
LYEL logo

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma (LYEL) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 20%
Buy 0%
Hold 60%
Sell 20%
Strong Sell 0%

Bulls say

Lyell Immunopharma Inc. possesses a promising pipeline of cell therapy products, including LYL797, LYL119, and LYL845, which leverage advanced ex vivo genetic and epigenetic T-cell reprogramming technologies aimed at treating solid tumors. The potential to expand the CAR-T market, particularly in non-Hodgkin lymphoma (NHL) and beyond, supports a favorable commercial outlook, especially if upcoming LYL119 data exceeds expectations. Additionally, the application of a 9% discount rate and a 2% terminal growth rate reflects confidence in the validated therapeutic potential of CD19-targeted approaches, positioning Lyell favorably within the crowded CAR-T landscape.

Bears say

Lyell Immunopharma reported a significant net loss of $0.69 per share for 4Q24, with projections indicating a worsening net loss of $0.73 for the full year 2025, highlighting the company's ongoing struggles in achieving profitability. The company also experienced a decline in the complete response (CR) rate for its product candidates, with a current 63% CR rate compared to a previously reported 77%, raising concerns about the efficacy of its trials. Additionally, despite slightly aligning R&D and SG&A expenses with projections, the company's overall financial outlook remains challenging due to high development risks associated with competing against established standard of care treatments in the cell therapy market.

Lyell Immunopharma (LYEL) has been analyzed by 5 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 0% recommend Buy, 60% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lyell Immunopharma (LYEL) Forecast

Analysts have given Lyell Immunopharma (LYEL) a Hold based on their latest research and market trends.

According to 5 analysts, Lyell Immunopharma (LYEL) has a Hold consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lyell Immunopharma (LYEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.